Melanoma Management

Melanoma Manag

2045-0885

2045-0893

Therapeutic Area

Dermatology, Diagnostic Imaging, Immunology, Nuclear Medicine, Oncology, Patient Safety, Pharmacology, Public Health, Surgery, Vaccines/Vaccinology

Clinicians, Dermatologists, Nuclear Medicine Physicians, Oncologists, Pharmacologists, Physicians, Physicians - Medicine, Radiation Oncologists, Surgeons, Surgical Oncologists

Skin cancer is on the rise. According to the World Health Organization, 132,000 melanoma skin cancers occur globally each year. While early-stage melanoma is usually relatively easy to treat, once disease spreads prognosis worsens considerably. Therefore, research into combating advanced-stage melanoma is a high priority. New and emerging therapies, such as monoclonal antibodies, B-RAF and KIT inhibitors, antiangiogenic agents and novel chemotherapy approaches hold promise for prolonging survival, but the search for a cure is ongoing. Melanoma Management publishes high-quality peer-reviewed articles on all aspects of melanoma, from prevention to diagnosis and from treatment of early-stage disease to late-stage melanoma and metastasis. The journal presents the latest research findings in melanoma research and treatment, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. Key topics covered include: Risk factors, prevention and sun safety education, Diagnosis, staging and grading, Surgical excision of melanoma lesions, Sentinel lymph node biopsy, Biological therapies, including immunotherapy and vaccination, Novel chemotherapy options, Treatment of metastasis, Prevention of recurrence, Patient care and quality of life. Melanoma Management delivers an accessible overview of current and future melanoma management options in a concise format that is ideal for the busy clinician. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal's Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including COPE, ICMJE and GPP3.

No associations affiliated with this journal

Future Medicine Ltd.

Electronic Circulation Submission to Acceptance Acceptance to Online Publication Rejection Rate Frequency Journal Contact Author Submission Guidelines